4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-025501
CHIEF FINANCIAL OFFICER sold 814 shares at $30.00 ($24,422)
- CHIEF FINANCIAL OFFICER acquired 814 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-18 | Option exercise 10b5-1 | +814 | $2.48 | $2,019 | 814 | D: show line 1 in the form |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-18 | Sale 10b5-1 | −814 | $30.00 | $24,422 | 0 | D: show line 2 in the form |
| Open-market sales · 814 sh · avg $30.00 · $24,422 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-10-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −814 | 180,056 | D: show line 3 in the form |
Loading xslF345X05/form4-10222024_081055.xml…